New studies on retatrutide, a dual activator for glucagon-like peptide-1 and gastric inhibitory polypeptide, demonstrate promising findings in managing obesity and type 2 diabetic condition. Early evidence from clinical assessments show considerable reductions in body weight and enhanced glucose